Last Updated: June 9, 2026

Aurobindo Pharma Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for AUROBINDO PHARMA

AUROBINDO PHARMA has five hundred and fifty-three approved drugs.

There are twenty-five tentative approvals on AUROBINDO PHARMA drugs.

Drugs and US Patents for Aurobindo Pharma

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aurobindo Pharma Ltd BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE bisoprolol fumarate; hydrochlorothiazide TABLET;ORAL 217922-002 Jan 21, 2026 AB RX No No ⤷  Start Trial ⤷  Start Trial
Aurobindo Pharma Ltd CETIRIZINE HYDROCHLORIDE HIVES RELIEF cetirizine hydrochloride TABLET;ORAL 090760-002 Aug 5, 2015 OTC No No ⤷  Start Trial ⤷  Start Trial
Aurobindo Pharma Ltd NICOTINE POLACRILEX nicotine polacrilex TROCHE/LOZENGE;ORAL 215357-001 May 13, 2022 OTC No No ⤷  Start Trial ⤷  Start Trial
Aurobindo Pharma CEFUROXIME AXETIL cefuroxime axetil TABLET;ORAL 065308-003 Mar 29, 2006 AB RX No Yes ⤷  Start Trial ⤷  Start Trial
Aurobindo Pharma ENALAPRIL MALEATE enalapril maleate SOLUTION;ORAL 216458-001 Jan 8, 2024 AB RX No No ⤷  Start Trial ⤷  Start Trial
Aurobindo Pharma GLIPIZIDE glipizide TABLET, EXTENDED RELEASE;ORAL 206928-002 May 12, 2017 AB RX No No ⤷  Start Trial ⤷  Start Trial
Aurobindo Pharma DABIGATRAN ETEXILATE MESYLATE dabigatran etexilate mesylate CAPSULE;ORAL 208039-001 May 14, 2025 AB RX No No ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Aurobindo Pharma

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Aurobindo Pharma Usa MAXZIDE hydrochlorothiazide; triamterene TABLET;ORAL 019129-001 Oct 22, 1984 4,105,783 ⤷  Start Trial
Aurobindo Pharma Usa MAXZIDE-25 hydrochlorothiazide; triamterene TABLET;ORAL 019129-003 May 13, 1988 4,444,769 ⤷  Start Trial
Aurobindo Pharma Usa MAXZIDE hydrochlorothiazide; triamterene TABLET;ORAL 019129-001 Oct 22, 1984 4,444,769 ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for AUROBINDO PHARMA drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe for Injection 100 mcg/vial and 500 mcg/vial ➤ Subscribe 2015-04-14
➤ Subscribe Delayed-release Tablets 20 mg ➤ Subscribe 2015-06-03
➤ Subscribe for Injection 200 mcg/vial ➤ Subscribe 2015-05-01
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.